Kronos Bio (Kronos Bio) 6-1 Month Momentum % : 40.05% (As of May. 12, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-12), Kronos Bio's 6-1 Month Momentum % is 40.05%.

The industry rank for Kronos Bio's 6-1 Month Momentum % or its related term are showing as below:

KRON's 6-1 Month Momentum % is ranked better than
73.22% of 1531 companies
in the Biotechnology industry
Industry Median: 2.29 vs KRON: 40.05

Competitive Comparison of Kronos Bio's 6-1 Month Momentum %

For the Biotechnology subindustry, Kronos Bio's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kronos Bio's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Kronos Bio's 6-1 Month Momentum % falls into.

Kronos Bio (NAS:KRON) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kronos Bio (NAS:KRON) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Kronos Bio 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Kronos Bio's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kronos Bio (Kronos Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402

Website

https://www.kronosbio.com

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Executives

Jorge Dimartino	officer: Chief Medical Officer & VP	C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore	officer: Chief Scientific Officer	C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz	officer: COO & General Counsel	3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger	director, 10 percent owner, officer: President & CEO	333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner	officer: Interim CFO	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130